Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance.
OBJECTIVE
Active surveillance with selective delayed intervention is a treatment regimen used in patients with low risk prostate cancer. Decision making is based on pretreatment prostate specific antigen, clinical stage and prostate biopsy results. We reviewed our experience with immediate repeat biopsy in patients eligible for active surveillance with selective delayed intervention.


METHODS
A retrospective review was done of the records of consecutive patients who underwent repeat biopsy within 3 months of a first positive biopsy from March 2002 to June 2007. Patients were considered eligible if they had prostate specific antigen less than 10 ng/ml, clinical stage T2a or less, Gleason pattern 3 or less, 3 or fewer positive cores and no single core with 50% or greater cancer involvement.


RESULTS
A total of 104 patients met eligibility criteria. Of the 104 repeat biopsies performed 27 (26%) were negative, 59 (57%) had a Gleason score of 6 or less and 17 (16%) had a Gleason score of 7. One patient had a Gleason score of 9, while 10 of 104 (10%) had greater than 3 cores involved on repeat biopsy and 12 (12%) had 50% or greater involvement of at least 1 core. Of 104 cases (27%) 28 were upgraded and/or up staged. Treated cases that were upgraded and/or up staged were more likely to show higher pathological stage and grade at radical prostatectomy than those that were not (p = 0.003 and p = 0.001, respectively).


CONCLUSIONS
Immediate repeat biopsy in cases of active surveillance with selective delayed intervention resulted in 27% being upgraded or up staged and those were more likely to show higher grade and stage disease at radical prostatectomy. We recommend repeat biopsy because it improved our discrimination of who are the best candidates for active surveillance with selective delayed intervention.
Berglund
Ryan K
RK
Division of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Masterson
Timothy A
TA
Vora
Kinjal C
KC
Eggener
Scott E
SE
Eastham
James A
JA
Guillonneau
Bertrand D
BD
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001707:Biopsy, Needle / Q000379:methods*; D001918:Brachytherapy / Q000379:methods / Q000706:statistics & numerical data; D015331:Cohort Studies; D051517:Digital Rectal Examination; D005500:Follow-Up Studies; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic / Q000379:methods*; D009367:Neoplasm Staging; D019370:Observation; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy / Q000379:methods / Q000706:statistics & numerical data; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D012189:Retrospective Studies; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D016019:Survival Analysis; D013997:Time Factors
D017430:Prostate-Specific Antigen
BJU Int. 2008 Jan;101(2):165-9
17850361
Urol Oncol. 2007 Nov-Dec;25(6):505-9
18047961
Cancer. 2007 Nov 15;110(10):2218-21
17893906
Prostate. 2007 Nov 1;67(15):1614-20
17823923
CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
17237035
N Engl J Med. 2005 May 12;352(19):1977-84
15888698
JAMA. 2005 May 4;293(17):2095-101
15870412
JAMA. 1997 Feb 12;277(6):467-71
9020270
JAMA. 1995 Jan 11;273(2):129-35
7799493
J Urol. 1994 Nov;152(5 Pt 2):1757-60
7523723
JAMA. 1994 Feb 2;271(5):368-74
7506797
N Engl J Med. 1994 Jan 27;330(4):242-8
8272085
J Urol. 2004 Apr;171(4):1520-4
15017211
J Urol. 2003 Nov;170(5):1792-7
14532778
J Urol. 2004 Feb;171(2 Pt 1):703-7; discussion 707-8
14713791
Urology. 2002 Apr;59(4):560-5
11927314
J Urol. 2002 Mar;167(3):1231-4
11832703
J Urol. 2001 Nov;166(5):1688-91
11586203
J Urol. 2000 Dec;164(6):1982-6
11061896
J Urol. 2000 Jan;163(1):174-8
10604340